Payment overview · 2025
General Payments
$692.59
32 reported records · 10 companies
Healthcare provider profile · identity verified
Matthew T Manzo, DO
Allopathic & Osteopathic Physicians|Family Medicine · PINEHURST, NC · NPI 1376591636
Verified facts
What the public records show
CMS Open Payments records show Matthew T Manzo, DO received $692.59 in general payments during 2025 across 32 reported records.
Lilly USA, LLC accounted for 30.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Vraylar by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 207 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 149 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $210.72 | 30.4% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $101.83 | 14.7% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $97.80 | 14.1% | 5 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $74.97 | 10.8% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $73.39 | 10.6% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $46.31 | 6.7% | 3 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $28.11 | 4.1% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $25.83 | 3.7% | 4 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $17.91 | 2.6% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $15.72 | 2.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $692.59 | 32 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $152.86 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $75.22 | 3 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $74.97 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $73.39 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $73.26 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $73.26 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $43.96 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $41.76 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $31.98 | 2 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $28.11 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $26.61 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $25.83 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $24.54 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $17.91 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $15.72 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.33 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 100 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 118 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 207 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 149 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
81 | 25 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
100 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
118 | 33 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
207 | 38 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
64 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
149 | 27 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 538 | 171 |
| Amlodipine Besylate | Amlodipine Besylate | 500 | 145 |
| Gabapentin | Gabapentin | 424 | 98 |
| Omeprazole | Omeprazole | 355 | 105 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 271 | 82 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 269 | 50 |
| Furosemide | Furosemide | 207 | 71 |
| Mounjaro | Tirzepatide | 207 | 38 |
| Levothyroxine Sodium | Levothyroxine Sodium | 200 | 66 |
| Metformin Hcl | Metformin Hcl | 199 | 63 |
| Pravastatin Sodium | Pravastatin Sodium | 191 | 61 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 175 | 54 |
| Fluticasone Propionate | Fluticasone Propionate | 173 | 56 |
| Oxycodone Hcl | Oxycodone Hcl | 166 | 43 |
| Metoprolol Succinate | Metoprolol Succinate | 159 | 47 |
| Lisinopril | Lisinopril | 158 | 52 |
| Hydrochlorothiazide | Hydrochlorothiazide | 156 | 50 |
| Ozempic | Semaglutide | 149 | 27 |
| Tizanidine Hcl | Tizanidine Hcl | 147 | 48 |
| Tamsulosin Hcl | Tamsulosin Hcl | 139 | 39 |
| Losartan Potassium | Losartan Potassium | 134 | 42 |
| Potassium Chloride | Potassium Chloride | 133 | 44 |
| Duloxetine Hcl | Duloxetine Hcl | 128 | 25 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 124 | 36 |
| Famotidine | Famotidine | 121 | 43 |
| Metformin Hcl Er | Metformin Hcl | 121 | 35 |
| Jardiance | Empagliflozin | 118 | 33 |
| Pantoprazole Sodium | Pantoprazole Sodium | 116 | 37 |
| Simvastatin | Simvastatin | 116 | 42 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 115 | 93 |
| Sertraline Hcl | Sertraline Hcl | 113 | 33 |
| Carvedilol | Carvedilol | 112 | 36 |
| Eliquis | Apixaban | 110 | 24 |
| Allopurinol | Allopurinol | 106 | 25 |
| Trazodone Hcl | Trazodone Hcl | 105 | 29 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 102 | 27 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 101 | 34 |
| Farxiga | Dapagliflozin Propanediol | 100 | 16 |
| Clonazepam | Clonazepam | 96 | 22 |
| Methylprednisolone | Methylprednisolone | 96 | 79 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 93 | 74 |
| Montelukast Sodium | Montelukast Sodium | 90 | 29 |
| Alprazolam | Alprazolam | 89 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 88 | 28 |
| Atenolol | Atenolol | 86 | 25 |
| Tramadol Hcl | Tramadol Hcl | 86 | 19 |
| Doxepin Hcl | Doxepin Hcl | 82 | 19 |
| Linzess | Linaclotide | 81 | 25 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 72 | 32 |
| Escitalopram Oxalate | Escitalopram Oxalate | 70 | 25 |
| Nortriptyline Hcl | Nortriptyline Hcl | 64 | 23 |
| Trulicity | Dulaglutide | 64 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 63 | 20 |
| Lorazepam | Lorazepam | 63 | 15 |
| Meclizine Hcl | Meclizine Hcl | 63 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 62 | 18 |
| Promethazine Hcl | Promethazine Hcl | 62 | 13 |
| Spironolactone | Spironolactone | 62 | 13 |
| Prednisone | Prednisone | 61 | 35 |
| Zolpidem Tartrate | Zolpidem Tartrate | 61 | suppressed |
| Celecoxib | Celecoxib | 59 | 16 |
| Buspirone Hcl | Buspirone Hcl | 58 | 11 |
| Diazepam | Diazepam | 57 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 57 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 55 | 19 |
| Ezetimibe | Ezetimibe | 54 | 15 |
| Glimepiride | Glimepiride | 53 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 52 | 14 |
| Januvia | Sitagliptin Phosphate | 50 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 50 | 11 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 49 | 19 |
| Benazepril Hcl | Benazepril Hcl | 49 | 17 |
| Pregabalin | Pregabalin | 49 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 49 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 46 | 12 |
| Colchicine | Colchicine | 46 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 46 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 46 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 46 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 43 | 15 |
| Fenofibrate | Fenofibrate | 42 | 15 |
| Metoclopramide Hcl | Metoclopramide Hcl | 42 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 42 | 15 |
| Valsartan | Valsartan | 42 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 41 | 11 |
| Ondansetron Odt | Ondansetron | 41 | 19 |
| Mirtazapine | Mirtazapine | 40 | 12 |
| Meloxicam | Meloxicam | 39 | 11 |
| Myrbetriq | Mirabegron | 39 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 38 | 21 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 38 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 38 | suppressed |
| Glipizide Er | Glipizide | 37 | suppressed |
| Lovastatin | Lovastatin | 36 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 36 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 35 | suppressed |
| Clonidine | Clonidine | 35 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 34 | 14 |
| Sucralfate | Sucralfate | 33 | suppressed |
| Fluconazole | Fluconazole | 32 | 17 |
| Topiramate | Topiramate | 32 | suppressed |
| Bupropion Xl | Bupropion Hcl | 31 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 30 | suppressed |
| Estradiol | Estradiol | 30 | suppressed |
| Nifedipine Er | Nifedipine | 30 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 30 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 29 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | suppressed |
| Oxycontin | Oxycodone Hcl | 29 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 28 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 27 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 27 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 27 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 27 | suppressed |
| Xtampza Er | Oxycodone Myristate | 27 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 26 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 26 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 26 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 26 | suppressed |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 23 | suppressed |
| Zaleplon | Zaleplon | 23 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | suppressed |
| Vraylar | Cariprazine Hcl | 22 | suppressed |
| Azithromycin | Azithromycin | 21 | 18 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 21 | suppressed |
| Finasteride | Finasteride | 21 | suppressed |
| Glipizide | Glipizide | 21 | suppressed |
| Primidone | Primidone | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Nitroglycerin | Nitroglycerin | 20 | 12 |
| Repatha Sureclick | Evolocumab | 20 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Nystatin | Nystatin | 19 | 12 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 19 | suppressed |
| Temazepam | Temazepam | 19 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 18 | 18 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 18 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Cilostazol | Cilostazol | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 15 |
| Vascepa | Icosapent Ethyl | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Klor-Con M20 | Potassium Chloride | 16 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 16 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 15 | suppressed |
| Cephalexin | Cephalexin | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 14 | 14 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 14 | suppressed |
| Premarin | Estrogens, Conjugated | 14 | suppressed |
| Sure Comfort Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 14 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 13 | suppressed |
| Dofetilide | Dofetilide | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Modafinil | Modafinil | 13 | suppressed |
| Emgality Syringe | Galcanezumab-Gnlm | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Risperidone | Risperidone | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $692.59 · 32 records | Lilly USA, LLC | AIRSUPRA, Cologuard Collection Kit, FARXIGA, JARDIANCE, Korlym, MOUNJARO, Ozempic, PURIFIED CORTROPHIN GEL, Rybelsus, SAPIEN 3 Ultra RESILIA, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, Wegovy, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error